Biomarker Approvals At Pre-IND Stage Requested For Orphan Drugs
Executive Summary
Updated draft white paper on expanding use of accelerated approval suggests FDA approve the use of biomarkers as surrogate endpoints in the pre-IND stage, which could enhance sponsors’ abilities to raise funds for trials and manufacturing.